# A Study of IMR-687 in Adult Participants With Sickle Cell Anemia (Homozygous HbSS or Sickle-β0 Thalassemia)

> **NCT03401112** · PHASE2 · COMPLETED · sponsor: **Cardurion Pharmaceuticals, Inc.** · enrollment: 100 (actual)

## Conditions studied

- Sickle Cell Disease

## Interventions

- **DRUG:** IMR-687
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03401112
- **Lead sponsor:** Cardurion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-26
- **Primary completion:** 2020-08-28
- **Final completion:** 2020-08-28
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2025-05-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03401112

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03401112, "A Study of IMR-687 in Adult Participants With Sickle Cell Anemia (Homozygous HbSS or Sickle-β0 Thalassemia)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03401112. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*